Aurinia Pharmaceuticals Inc.
AUPH
$8.18
$0.080.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 5.75M | -22.55M | -50.35M | -62.56M | -78.02M |
| Total Depreciation and Amortization | 19.45M | 19.53M | 19.90M | 15.78M | 11.65M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.74M | 29.21M | 28.18M | 29.51M | 38.52M |
| Change in Net Operating Assets | 5.45M | 2.40M | 547.00K | -3.12M | -5.61M |
| Cash from Operations | 44.39M | 28.59M | -1.72M | -20.39M | -33.46M |
| Capital Expenditure | -281.00K | -299.00K | -194.00K | -371.00K | -718.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 39.54M | -5.92M | -15.15M | 18.04M | -5.99M |
| Cash from Investing | 39.26M | -6.22M | -15.35M | 17.67M | -6.71M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11.99M | -15.50M | -16.03M | -12.80M | -10.03M |
| Issuance of Common Stock | 9.27M | 4.59M | 5.51M | 5.56M | 7.17M |
| Repurchase of Common Stock | -46.37M | -20.71M | -20.71M | -14.58M | -2.28M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -49.09M | -31.62M | -31.23M | -21.82M | -5.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 34.56M | -9.26M | -48.30M | -24.54M | -45.30M |